Differentiation-Dependent Doxorubicin Toxicity on H9c2 Cardiomyoblasts
- 29 June 2012
- journal article
- Published by Springer Nature in Cardiovascular Toxicology
- Vol. 12 (4) , 326-340
Abstract
A characteristic component of the anti-neoplastic doxorubicin (DOX)-induced cardiac toxicity is the delayed and persistent toxicity, with cancer childhood survivors developing cardiac failure later in life. The mechanisms behind this persistent toxicity are unknown, although one of the consequences of early childhood treatment with DOX is a specific removal of cardiac progenitor cells. DOX treatment may be more toxic to undifferentiated muscle cells, contributing to impaired cardiac development and toxicity persistence. H9c2 myoblasts, a rat embryonic cell line, which has the ability to differentiate into a skeletal or cardiac muscle phenotype, can be instrumental in understanding DOX cytotoxicity in different differentiation stages. H9c2 cell differentiation results in decreased cell proliferation and increased expression of a differentiated muscle marker. Differentiated H9c2 cells accumulated more DOX and were more susceptible to DOX-induced cytotoxicity. Differentiated cells had increased levels of mitochondrial superoxide dismutase and Bcl-xL, an anti-apoptotic protein. Of critical importance for the mechanisms of DOX toxicity, p53 appeared to be equally activated regardless of the differentiation state. We suggest that although more differentiated H9c2 muscle cells appear to have more basal mechanisms that would predict higher protection, DOX toxicity is higher in the differentiated population. The results are instrumental in the understanding of stress responses of this specific cell line in different differentiation stages to the cardiotoxicity caused by anthracyclines.Keywords
This publication has 53 references indexed in Scilit:
- Bcl-xL regulates mitochondrial energetics by stabilizing the inner membrane potentialJournal of Cell Biology, 2011
- The Permeability Transition Pore Controls Cardiac Mitochondrial Maturation and Myocyte DifferentiationDevelopmental Cell, 2011
- Inhibition of Rac1 signaling by lovastatin protects against anthracycline-induced cardiac toxicityCell Death & Disease, 2011
- Traveling Bax and Forth from Mitochondria to Control ApoptosisCell, 2011
- Anthracycline Cardiomyopathy Is Mediated by Depletion of the Cardiac Stem Cell Pool and Is Rescued by Restoration of Progenitor Cell FunctionCirculation, 2010
- Cardioprotection by resveratrol: a novel mechanism via autophagy involving the mTORC2 pathwayCardiovascular Research, 2009
- Down-regulation of SM22/transgelin gene expression during H9c2 cells differentiationMolecular and Cellular Biochemistry, 2009
- Differences in doxorubicin-induced apoptotic signaling in adult and immature cardiomyocytesFree Radical Biology and Medicine, 2008
- Absence of a Universal Mechanism of Mitochondrial Toxicity by Nucleoside AnalogsAntimicrobial Agents and Chemotherapy, 2007
- A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingAnalytical Biochemistry, 1976